ES2541364T3 - Péptido - Google Patents

Péptido Download PDF

Info

Publication number
ES2541364T3
ES2541364T3 ES10779020.6T ES10779020T ES2541364T3 ES 2541364 T3 ES2541364 T3 ES 2541364T3 ES 10779020 T ES10779020 T ES 10779020T ES 2541364 T3 ES2541364 T3 ES 2541364T3
Authority
ES
Spain
Prior art keywords
leu
pro
gln
phe
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10779020.6T
Other languages
English (en)
Inventor
Ganesh Chandramowli
Babu Rakesh Kumar Bandi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unilever NV
Original Assignee
Unilever NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever NV filed Critical Unilever NV
Application granted granted Critical
Publication of ES2541364T3 publication Critical patent/ES2541364T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Péptido seleccionado de: (i) SEQ ID NO:1 es Xm-Leu-Ser-Arg-His-Val-Leu-Gln-Xn (Xm-LSRHVLQ-Xn); o (ii) SEQ ID NO:2 es Xm-His-Gly-His-Pro-Phe-Ala-Pro-Xn (Xm-HGHPFAP-Xn), en el que cada X se selecciona independientemente del grupo que consiste en Gly, Ala, Val, Leu, Ile, Ser, Thr, Phe, Tyr, Trp, Cys, Pro, His, Glu, Asp, Gln, Asn, Lys, Arg y Met, y m y n son cada uno independientemente un número entero desde 0 hasta 5.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9

Claims (1)

  1. imagen1
ES10779020.6T 2009-12-16 2010-11-23 Péptido Active ES2541364T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2898MU2009 2009-12-16
INMU28982009 2009-12-16
PCT/EP2010/067972 WO2011072991A1 (en) 2009-12-16 2010-11-23 Peptide

Publications (1)

Publication Number Publication Date
ES2541364T3 true ES2541364T3 (es) 2015-07-17

Family

ID=43533119

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10779020.6T Active ES2541364T3 (es) 2009-12-16 2010-11-23 Péptido

Country Status (11)

Country Link
US (1) US8580920B2 (es)
EP (1) EP2512496B1 (es)
JP (1) JP5752145B2 (es)
CN (1) CN103313723B (es)
BR (1) BR112012013095A2 (es)
CA (1) CA2782131C (es)
EA (1) EA022214B1 (es)
ES (1) ES2541364T3 (es)
MX (1) MX2012007034A (es)
WO (1) WO2011072991A1 (es)
ZA (1) ZA201203722B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3058936T3 (pl) * 2013-10-18 2019-09-30 Universidade Do Minho Kompozycja peptydów i jej zastosowania
US11712410B2 (en) 2018-09-05 2023-08-01 K18, Inc. Composition for improving hair health
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0389950A1 (en) * 1989-03-23 1990-10-03 Lion Corporation Melanocyte-stimulating hormone inhibitor and external preparation containing the same
GB9719195D0 (en) * 1997-09-09 1997-11-12 Unilever Plc Skin lightening composition
JP2001002527A (ja) 1999-06-22 2001-01-09 Lion Corp 皮膚外用剤組成物
AU2001263006A1 (en) * 2000-05-18 2001-11-26 Hyseq, Inc. Novel nucleic acids and polypeptides
US20070060743A1 (en) * 2001-05-16 2007-03-15 Tang Y Tom Novel nucleic acids and polypeptides
EP1615991A4 (en) 2003-04-03 2007-12-19 Bristol Myers Squibb Co POLYNUCLEOTIDE ENCODING A NEW HUMAN P2X7 SPLICE VARIANT CALLED HBMYP2X7V
CA2644273A1 (en) 2006-04-05 2008-03-27 Metanomics Gmbh Process for the production of a fine chemical
FR2900573B1 (fr) * 2006-05-05 2014-05-16 Sederma Sa Nouvelles compositions cosmetiques renfermant au moins un peptide contenant au moins un cycle aromatique bloque
EP2009023A1 (en) * 2007-06-04 2008-12-31 Rentschler Beteiligungs GmbH Novel peptides and their use for the treatment of edema

Also Published As

Publication number Publication date
CN103313723B (zh) 2015-02-04
MX2012007034A (es) 2012-07-04
US20120263665A1 (en) 2012-10-18
JP2013514291A (ja) 2013-04-25
EP2512496B1 (en) 2015-04-01
WO2011072991A1 (en) 2011-06-23
US8580920B2 (en) 2013-11-12
CA2782131A1 (en) 2011-06-23
CA2782131C (en) 2018-12-11
CN103313723A (zh) 2013-09-18
EA201200889A1 (ru) 2013-01-30
EA022214B1 (ru) 2015-11-30
BR112012013095A2 (pt) 2017-05-16
EP2512496A1 (en) 2012-10-24
JP5752145B2 (ja) 2015-07-22
ZA201203722B (en) 2013-08-28

Similar Documents

Publication Publication Date Title
PE20240015A1 (es) Proteinas de fusion gdf15 y usos de estas
PE20121393A1 (es) Analogo peptidico de oxintomodulina
PE20120358A1 (es) Mutantes fgf21 y usos de los mismos
AU2019250206A1 (en) Novel immunogenic peptides
MX2017004488A (es) Composiciones farmaceuticas que comprenden variantes peptidicos y metodos para su uso.
RU2011138011A (ru) Миметики аполипопротеина а-i
ES2513716T3 (es) Enzimas lecitina-colesteros acitransferasa modificadas
CL2011000086A1 (es) Anticuerpo aislado o proteina funcional contra el polipeptido baffr que inhibe la proliferacion de celulas b; secuencia nucleotidicas de dicho anticuerpo; vector y celula huesped que comprende dicha secuencia; y su uso para tratar enfermedades autoinmunes o neoplasias de celulas b.
AR058888A1 (es) Formulaciones estabilizadas que contienen anticuerpos
NZ603016A (en) Novel immunotherapy against several tumors including neuronal and brain tumors
MX2009005466A (es) Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas, incluyendo receptor de factor de crecimiento tipo insulina-i.
RS54215B1 (en) COMPOSITIONS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF CANCER
RU2010116278A (ru) Модифицированная константная область антитела
RU2017119773A (ru) Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение
EA201291362A1 (ru) Слитый белок против злокачественных новообразований
NZ595361A (en) Chimeric factor h binding proteins (fhbp) and methods of use
CL2007001710A1 (es) Compuestos derivados de amino-pirazolopiridina sustituidos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como tumores, artritis reumatoide, enfermedades de crecimiento vascular desregulado, entre otras.
MY194925A (en) Composition of fish skin collagen peptides and use thereof as a drug
ES2541364T3 (es) Péptido
PE20130199A1 (es) Proteina de fusion robo1-fc y su utilizacion en el tratamiento de tumores
NZ609216A (en) Anticancer fusion protein
NZ603196A (en) Methods of use of soluble cd24 for therapy of rheumatoid arthritis
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
NZ708990A (en) Method for activating helper t cell
EA201990298A1 (ru) Способы и композиции для лечения рака